Journal for ImmunoTherapy of Cancer (Nov 2020)
568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2020)